These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3721 related articles for article (PubMed ID: 7583979)

  • 21. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
    Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
    Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The promise of T-lymphocyte immunotherapy for the treatment of malignant disease.
    Thomas AK; June CH
    Cancer J; 2001; 7 Suppl 2():S67-75. PubMed ID: 11777267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive cellular immunotherapy of cancer: future perspectives.
    Stevenson HC
    Immunol Ser; 1989; 48():229-36. PubMed ID: 2488324
    [No Abstract]   [Full Text] [Related]  

  • 25. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).
    Wank R; Song X; Gu S; Laumbacher B
    Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically modulating T-cell function to target cancer.
    Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
    Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy of malignant melanoma].
    Flageul B; Miclea JM; Bensussan A; Degos L
    Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
    [No Abstract]   [Full Text] [Related]  

  • 31. Adoptive cellular therapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1992; 13():191-204. PubMed ID: 1389910
    [No Abstract]   [Full Text] [Related]  

  • 32. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cancer immunotherapy: immunologic bases, reality and hopes].
    Dietrich PY; Farace F; Caignard A; Escudier B; Triebel F
    Bull Cancer; 1993 Jul; 80(7):584-600. PubMed ID: 8204939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.
    Hwu P; Rosenberg SA
    Cancer Detect Prev; 1994; 18(1):43-50. PubMed ID: 8162605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic approaches to adoptive cellular therapy of malignancy.
    Arca MJ; Mulé JJ; Chang AE
    Semin Oncol; 1996 Feb; 23(1):108-17. PubMed ID: 8607021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
    Knutson KL; Disis ML
    Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreased tumor surveillance after adoptive T-cell therapy.
    Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
    Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
    Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
    Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 187.